EG BioMed is a Taiwanese biomedical startup founded in 2022, focused on innovative cancer detection and management technologies. Our goal is to develop advanced cancer screening and monitoring procedures.

Foundation and Mission
EG BioMed CO., LTD. originated as a spin-off from Taipei Medical University. Our mission is to provide accurate, reliable cancer detection methods for clinical practice.

Circulating Cell-Free DNA Methylation Tests
We develop cfDNA methylation blood tests for:
* Early Detection: Identifying cancer at early stages.
* Monitoring Progression: Tracking patients for timely interventions.
We have validated over 10 cancer-specific gene methylation biomarkers, advancing personalized medicine with tailored solutions.

International Expansion
EG BioMed US Inc. in Bothell, Washington, aims to meet global demand. We are seeking CLIA and Washington State certifications for U.S. operations, clinical trials, and FDA applications.

EG Clinical Laboratory
Established in 2024, EG Clinical Laboratory focuses on:
* Innovative Detection: Using cutting-edge blood methylation technology.
* Accuracy and Reliability: Ensuring high precision and trustworthy results.
EG Clinical Laboratory aims to set industry standards and improve health outcomes through precision testing.

EG BioMed

Org chart

Teams

Offices